Drug intelligence / Profile preview

hBRCA84D CAR-T cells

Development stage: Phase 1
Lead developer: Cancer Research UK
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

hBRCA84D CAR-T cells is an autologous, multi-modular chimeric antigen receptor (CAR) T-cell therapy being developed by Cancer Research UK (CRUK) and the UCL Cancer Trials Centre (University College London). The therapy consists of the patient's own T cells genetically engineered to express a CAR construct targeting B7-H3 (CD276), a cell surface glycoprotein that is highly upregulated in several pediatric solid tumors. It is currently being evaluated in the Phase 1 MIGHTY clinical trial in the United Kingdom for children, adolescents, and young adults with relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, or desmoplastic small round cell tumour, administered following fludarabine and cyclophosphamide lymphodepletion.

Other names: hBRCA84D CAR T cellshBRCA-84D CAR T cellshBRCA 84D CAR T cellsautologous hBRCA84D CAR T cellsB7-H3-targeted hBRCA84D CAR-T cellsB-7-H3-targeted hBRCA84D CAR-T cellsB 7-H3-targeted hBRCA84D CAR-T cells

Targets

B7-H3

Beyond the preview

Go deeper on hBRCA84D CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hBRCA84D CAR-T cells.

Explore the full profile